333 related articles for article (PubMed ID: 9748545)
1. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme.
Burden DA; Osheroff N
Biochim Biophys Acta; 1998 Oct; 1400(1-3):139-54. PubMed ID: 9748545
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.
Fortune JM; Osheroff N
Prog Nucleic Acid Res Mol Biol; 2000; 64():221-53. PubMed ID: 10697411
[TBL] [Abstract][Full Text] [Related]
3. Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes.
Wilstermann AM; Osheroff N
Curr Top Med Chem; 2003; 3(3):321-38. PubMed ID: 12570766
[TBL] [Abstract][Full Text] [Related]
4. Catalytic function of DNA topoisomerase II.
Osheroff N; Zechiedrich EL; Gale KC
Bioessays; 1991 Jun; 13(6):269-73. PubMed ID: 1654050
[TBL] [Abstract][Full Text] [Related]
5. The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing.
Deweese JE; Osheroff N
Nucleic Acids Res; 2009 Feb; 37(3):738-48. PubMed ID: 19042970
[TBL] [Abstract][Full Text] [Related]
6. Etoposide, topoisomerase II and cancer.
Baldwin EL; Osheroff N
Curr Med Chem Anticancer Agents; 2005 Jul; 5(4):363-72. PubMed ID: 16101488
[TBL] [Abstract][Full Text] [Related]
7. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
Marx G; Zhou H; Graves DE; Osheroff N
Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321
[TBL] [Abstract][Full Text] [Related]
8. Analysis of eukaryotic DNA topoisomerases and topoisomerase-directed drug effects.
Boege F
Eur J Clin Chem Clin Biochem; 1996 Nov; 34(11):873-88. PubMed ID: 8960461
[TBL] [Abstract][Full Text] [Related]
9. Cleavage of plasmid DNA by eukaryotic topoisomerase II.
Bandele OJ; Osheroff N
Methods Mol Biol; 2009; 582():39-47. PubMed ID: 19763940
[TBL] [Abstract][Full Text] [Related]
10. A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase II alpha.
Jensen LH; Renodon-Cornière A; Nitiss KC; Hill BT; Nitiss JL; Jensen PB; Sehested M
Biochem Pharmacol; 2003 Aug; 66(4):623-31. PubMed ID: 12906927
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase II Poisons: Converting Essential Enzymes into Molecular Scissors.
Vann KR; Oviatt AA; Osheroff N
Biochemistry; 2021 Jun; 60(21):1630-1641. PubMed ID: 34008964
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerases as anticancer targets.
Delgado JL; Hsieh CM; Chan NL; Hiasa H
Biochem J; 2018 Jan; 475(2):373-398. PubMed ID: 29363591
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase II, genotoxicity, and cancer.
McClendon AK; Osheroff N
Mutat Res; 2007 Oct; 623(1-2):83-97. PubMed ID: 17681352
[TBL] [Abstract][Full Text] [Related]
14. Novel xanthone-polyamine conjugates as catalytic inhibitors of human topoisomerase IIα.
Minniti E; Byl JAW; Riccardi L; Sissi C; Rosini M; De Vivo M; Minarini A; Osheroff N
Bioorg Med Chem Lett; 2017 Oct; 27(20):4687-4693. PubMed ID: 28919339
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme.
Pommier Y; Pourquier P; Fan Y; Strumberg D
Biochim Biophys Acta; 1998 Oct; 1400(1-3):83-105. PubMed ID: 9748515
[TBL] [Abstract][Full Text] [Related]
16. Drugs acting on DNA topoisomerases: recent advances and future perspectives.
Gatto B; Capranico G; Palumbo M
Curr Pharm Des; 1999 Mar; 5(3):195-215. PubMed ID: 10066890
[TBL] [Abstract][Full Text] [Related]
17. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
18. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
19. A novel homogenous assay for topoisomerase II action and inhibition.
Jahnz M; Medina MA; Schwille P
Chembiochem; 2005 May; 6(5):920-6. PubMed ID: 15812853
[TBL] [Abstract][Full Text] [Related]
20. Novel trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-ones act as covalent poisons of human topoisomerase IIα.
Infante Lara L; Sledge A; Laradji A; Okoro CO; Osheroff N
Bioorg Med Chem Lett; 2017 Feb; 27(3):586-589. PubMed ID: 27998679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
